Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

This phase II trial studies the effects of binimetinib and encorafenib in treating patients with melanoma that has spread to the central nervous system (metastases). Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and encorafenib may help control melanoma that has spread to the brain.

Trial Details

NCT ID
NCT05026983
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Binimetinib
  • Encorafenib
  • Questionnaire Administration
Locations (sample)
  • Houston, Texas, United States

Key Eligibility Criteria

  • Able to provide written informed consent.
  • Age \>= 18 years at the time of informed consent
  • Histologically confirmed diagnosis of melanoma
  • Presence of BRAFV600 mutation in tumor tissue previously determined by a local assay (including immunohistochemistry \[IHC\]) at any time prior to …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →